Cancer diagnostics startup OneCell Diagnostics has raised $16 million in its Series A round led by Celesta Capital. Tenacity Ventures, Cedars Sinai, Eragon, and Singularity Ventures have also participated in the round.
The proceeds will be used to expand to the US market for OncoIndx Alfa, a next-generation liquid biopsy test that detects circulating tumor cells, OneCell said in a press release.
Founded in 2021, OneCell’s technology uses next-generation sequencing, strong bioinformatics, AI/ML, and data analytics to create multi-omics biomarkers.
“We see a future where everyone has access to high-quality, life-saving cancer testing and this funding is a powerful validation of our vision,” said Mohan Uttarwar, CEO and co-founder at OneCell Diagnostics.
OncoIndx Alfa offers rich biomarkers that advance precision diagnosis and treatment of cancer, including use cases such as treatment response monitoring, disease progression, recurrence, and more.
According to its website, OneCell partners with All India Institute of Medical Science, New Delhi, and Tata Memorial Centre. It also has strategic academic and industry partners including Harvard Medical School and Stanford University, among others.
The company has already introduced a series of products and tested its cell biopsy technology in nearly 10,000 patients to date in India.
